Cargando…

RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES

OBJECTIVE: The toxicities associated with stereotactic radiosurgery (SRS) are important factors when considering treatment options and supportive management for patients with brain metastases. We assessed the association between brain metastasis location and rates of toxicity after SRS. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Boya, Kaidar-Person, Orit, Sasaki-Adams, Deanna, Jaikumar, Sivakumar, Ewend, Matthew, Nakamura, Zev, Chen, Ronald, Zagar, Timothy, Tepper, Joel, Marks, Lawrence, Khagi, Simon, Shen, Colette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213166/
http://dx.doi.org/10.1093/noajnl/vdz014.133
_version_ 1783531744550453248
author Wang, Boya
Kaidar-Person, Orit
Sasaki-Adams, Deanna
Jaikumar, Sivakumar
Ewend, Matthew
Nakamura, Zev
Chen, Ronald
Zagar, Timothy
Tepper, Joel
Marks, Lawrence
Khagi, Simon
Shen, Colette
author_facet Wang, Boya
Kaidar-Person, Orit
Sasaki-Adams, Deanna
Jaikumar, Sivakumar
Ewend, Matthew
Nakamura, Zev
Chen, Ronald
Zagar, Timothy
Tepper, Joel
Marks, Lawrence
Khagi, Simon
Shen, Colette
author_sort Wang, Boya
collection PubMed
description OBJECTIVE: The toxicities associated with stereotactic radiosurgery (SRS) are important factors when considering treatment options and supportive management for patients with brain metastases. We assessed the association between brain metastasis location and rates of toxicity after SRS. METHODS: We conducted a retrospective single-institution review of 170 patients treated with SRS for brain metastases from 2008–2016 with median follow-up of 8.6 months. Typical SRS doses were 18-20Gy in 1 fraction (lesions < 2cm), 18-21Gy in 3 fractions (lesions 2-3cm), and 25-30Gy in 5 fractions (lesions >3cm). Toxicity measures evaluated included radiation necrosis, seizure, and dexamethasone requirement. RESULTS: A total of 221 lesions were treated among frontal (29%), cerebellar (23%), parietal (16%), temporal (15%), occipital (14%), and other (brainstem, thalamus, basal ganglia) (4%) regions. The rate of SRS-related radionecrosis was 4% for all patients and significantly correlated with metastasis volume (increasing from 1% to 7% for lesions ≤1cm(3) to >3cm(3)) and prior whole brain radiotherapy (WBRT) but not with metastasis location or prior resection on multi-variable analysis (P< 0.05). Post-SRS seizure occurred in 9% of all patients but was significantly higher for primary motor cortex and sensory cortex lesions, associated with 52% and 33% seizure rates, respectively (P< 0.05). Of patients who initially presented with seizure and were on anti-epileptic medication during SRS, 53% had no further seizures, while 47% did have post-SRS seizures, nearly all with motor cortex lesions. Only 5% of patients had new-onset seizure after SRS, related to lesion hemorrhage or motor cortex location. Dexamethasone use >3 months post-SRS was higher for motor strip lesions. CONCLUSION: Brain metastasis location in the primary motor cortex was associated with higher rates of post-SRS seizure, including new-onset seizures and breakthrough seizures on anti-epileptic medication during SRS. Rates of radionecrosis were associated with lesion volume and prior WBRT but not with metastasis location.
format Online
Article
Text
id pubmed-7213166
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72131662020-07-07 RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES Wang, Boya Kaidar-Person, Orit Sasaki-Adams, Deanna Jaikumar, Sivakumar Ewend, Matthew Nakamura, Zev Chen, Ronald Zagar, Timothy Tepper, Joel Marks, Lawrence Khagi, Simon Shen, Colette Neurooncol Adv Abstracts OBJECTIVE: The toxicities associated with stereotactic radiosurgery (SRS) are important factors when considering treatment options and supportive management for patients with brain metastases. We assessed the association between brain metastasis location and rates of toxicity after SRS. METHODS: We conducted a retrospective single-institution review of 170 patients treated with SRS for brain metastases from 2008–2016 with median follow-up of 8.6 months. Typical SRS doses were 18-20Gy in 1 fraction (lesions < 2cm), 18-21Gy in 3 fractions (lesions 2-3cm), and 25-30Gy in 5 fractions (lesions >3cm). Toxicity measures evaluated included radiation necrosis, seizure, and dexamethasone requirement. RESULTS: A total of 221 lesions were treated among frontal (29%), cerebellar (23%), parietal (16%), temporal (15%), occipital (14%), and other (brainstem, thalamus, basal ganglia) (4%) regions. The rate of SRS-related radionecrosis was 4% for all patients and significantly correlated with metastasis volume (increasing from 1% to 7% for lesions ≤1cm(3) to >3cm(3)) and prior whole brain radiotherapy (WBRT) but not with metastasis location or prior resection on multi-variable analysis (P< 0.05). Post-SRS seizure occurred in 9% of all patients but was significantly higher for primary motor cortex and sensory cortex lesions, associated with 52% and 33% seizure rates, respectively (P< 0.05). Of patients who initially presented with seizure and were on anti-epileptic medication during SRS, 53% had no further seizures, while 47% did have post-SRS seizures, nearly all with motor cortex lesions. Only 5% of patients had new-onset seizure after SRS, related to lesion hemorrhage or motor cortex location. Dexamethasone use >3 months post-SRS was higher for motor strip lesions. CONCLUSION: Brain metastasis location in the primary motor cortex was associated with higher rates of post-SRS seizure, including new-onset seizures and breakthrough seizures on anti-epileptic medication during SRS. Rates of radionecrosis were associated with lesion volume and prior WBRT but not with metastasis location. Oxford University Press 2019-08-12 /pmc/articles/PMC7213166/ http://dx.doi.org/10.1093/noajnl/vdz014.133 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Wang, Boya
Kaidar-Person, Orit
Sasaki-Adams, Deanna
Jaikumar, Sivakumar
Ewend, Matthew
Nakamura, Zev
Chen, Ronald
Zagar, Timothy
Tepper, Joel
Marks, Lawrence
Khagi, Simon
Shen, Colette
RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title_full RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title_fullStr RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title_full_unstemmed RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title_short RADI-42. ASSOCIATION BETWEEN TUMOR LOCATION AND TOXICITY OUTCOMES AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
title_sort radi-42. association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213166/
http://dx.doi.org/10.1093/noajnl/vdz014.133
work_keys_str_mv AT wangboya radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT kaidarpersonorit radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT sasakiadamsdeanna radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT jaikumarsivakumar radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT ewendmatthew radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT nakamurazev radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT chenronald radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT zagartimothy radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT tepperjoel radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT markslawrence radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT khagisimon radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases
AT shencolette radi42associationbetweentumorlocationandtoxicityoutcomesafterstereotacticradiosurgeryforbrainmetastases